Form 4: Vivani Medical Executive Donald Dwyer Acquires Stock Options and RSUs

Donald Dwyer, Chief Business Officer of Vivani Medical, reports acquisition of stock options and restricted stock units (RSUs) in the company.

Summary

• On May 12, 2025, Donald Dwyer, the Chief Business Officer of Vivani Medical, Inc., acquired 70,000 common stock options at an exercise price of $1.03.
• These options vest 25% after one year and then monthly over the subsequent 36 months, contingent upon continued service.
• Dwyer also acquired 35,000 performance-based RSUs.
• These RSUs vest in three stages based on the stock price closing at or above $3.15 for three consecutive days, with subsequent vesting milestones one and two years after the initial market condition is met, also contingent upon continued service.
• The RSUs will expire if the stock price does not reach the $3.15 target within four years from the grant date.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, indicating a positive alignment of management and shareholder interests. The performance-based RSUs suggest confidence in future stock price appreciation.

Positives

• The vesting of stock options and RSUs is tied to continued service, aligning the executive's interests with the company's long-term success.
• The performance-based RSUs incentivize the executive to drive the stock price higher, benefiting shareholders.

Risks

• The performance-based RSUs may expire if the stock price does not reach $3.15 within four years, potentially leading to a loss of incentive for the executive.
• The vesting of both options and RSUs is contingent upon continued service, creating a risk if the executive leaves the company before full vesting.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules of the options and RSUs suggest a multi-year horizon for executive incentives.

Industry Context

Granting stock options and RSUs to executives is a common practice in the pharmaceutical and biotech industries to align management's interests with shareholder value and incentivize long-term performance.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation tools in the biotech industry.
• Vesting schedules tied to both time and performance metrics are also common to incentivize long-term value creation.
• Comparable companies often use similar equity-based compensation plans to attract and retain key personnel.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with increasing shareholder value.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates

Keywords

Vivani Medical, Donald Dwyer, stock options, RSUs, Form 4, executive compensation, vesting, performance-based, VANI